

#23/F
Goiga
3/8/14
PATENT



Docket No. 17282 CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Steward et al.)
)
Serial No.: 09/548,409)
Conf. No.: 7255)
Filed: April 13, 2000)
)
For: Compositions and Methods)
For the Treatment of Pancreatitis)
_____)

Group Art Unit: 1644
Examiner: Nolan, P.

AMENDMENT C

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

This communication is in reply to the Office Action mailed June 25, 2003. Applicants have the following comments.

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (Label No. EV193716473US) in an envelope addressed to: Mail Stop RCE; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: 9/22/2003 Person making Deposit: BONNIE FERGUSON
Signature: Bonnie Ferguson Date of Signature: 9/22/2003

RECEIVED
SEP 26 2003
OFFICE OF PETITIONS

AMENDMENT

1. (Previously amended) A composition for the treatment of acute pancreatitis in a mammal comprising, a first element comprising a binding element able to specifically bind a pancreatic acinar cell CCK receptor under physiological conditions, a second element comprising a translocation element derived from a clostridial neurotoxin heavy chain able to facilitate the transfer of a polypeptide across a vesicular membrane, and a third element comprising a therapeutic element derived from a clostridial neurotoxin light chain able, when present in the cytoplasm of a pancreatic cell, to inhibit enzymatic secretion by said pancreatic cell.

2. (Cancelled)

F₁
3. (Original) The composition of claim 1 wherein said therapeutic element will cleave a SNARE protein and cleavage of said SNARE protein inhibits said secretion.

4. (Original) The composition of claim 3 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.

5. (Original) The composition of claim 2 wherein said therapeutic element will cleave a SNARE protein, wherein cleavage of said SNARE protein inhibits said secretion.

6. (Original) The composition of claim 5 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.

7. (Original) The composition of claim 5 wherein said CCK receptor is the human CCK A receptor.

8. (Original) The composition of claim 7 wherein the binding element of said

therapeutic polypeptide comprises a human CCK A amino acid sequence modified by the presence of a C-terminal amidated phenylalanine and a sulfated tyrosine at the position 7 residues from the carboxyl terminus.

9. (Original) The composition of claim 8 wherein said CCK A amino acid sequence comprises SEQ ID NO: 6.

10. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 5.

11. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 4.

12. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 3.

13. (Original) The composition of claim 9 wherein said CCK A amino acid sequence comprises SEQ ID NO: 2.

14-19. (Cancelled)
